Andrew Allen

Co-founder, President and CEO

Gritstone Oncology

Dr Andrew Allen, MD, PhD co-founded Gritstone Oncology, Inc. (NASDAQ:GRTS) and has served as President and Chief Executive Officer and a member of the board of directors since August 2015. Prior to Gritstone, in April 2009, he co-founded Clovis Oncology (NASDAQ:CLVS) and served as its executive vice president of clinical and preclinical development and chief medical officer until 2015. Prior to that, he was chief medical officer at Pharmion Corporation from 2006 to 2008 when it was acquired by Celgene. He has also served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Epizyme (NASDAQ:EPZM), TCR2 Therapeutics (NASDAQ:TCRR), Sierra Oncology (NASDAQ:SRRA) and Revitope Oncology (Private) and previously served on the board of directors of Cell Design Labs from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. He qualified in medicine at Oxford University and received a PhD in immunology from Imperial College of Science, Technology and Medicine in London.